In vivo histopathological staging in C9orf72-associated ALS: A tract of interest DTI study

Highlights

• •DTI showed a corticoefferent involvement pattern in ALS with C9orf72 expansion.
• •C9orf72 expansion showed alterations of ALS-related tract systems similar to sporadic patients.
• •DTI showed differences in the propagation patterns between genetic ALS types in vivo.

Abstract

Background

Diffusion tensor imaging (DTI) can identify amyotrophic lateral sclerosis (ALS)-associated patterns of brain alterations at the group level according to a neuropathological staging system.

Objective

The study was designed to investigate the in vivo staging in ALS patients with the C9orf72 expansion and potential differences to ALS patients with the SOD1 mutation.

Methods

DTI-based white matter mapping was performed both by an unbiased voxel-wise statistical comparison and by a hypothesis-guided tract-wise analysis of fractional anisotropy (FA) maps according to the ALS-staging pattern for 27 ALS patients with C9orf72 expansion vs 15 ALS patients with SOD1 mutation vs 32 matched healthy controls. Clinical and neuropsychological data were acquired and correlated to DTI data.

Results

The analysis of white matter integrity demonstrated regional FA reductions along the CST and also in frontal and prefrontal brain areas according to the proposed propagation pattern for the ALS patients with C9orf72 expansion and sporadic patients. This pattern could not be identified for the SOD1 mutation at the group level. In contrast, in the tract-specific analysis according to the neuropathological ALS-staging pattern, C9orf72 expansion ALS patients showed significant alterations of ALS-related tract systems similar to sporadic patients.

Conclusions

The DTI study including the tract-of-interest-based analysis showed a microstructural corticoefferent involvement pattern according to the staging scheme in C9orf72-associated ALS patients but not in the SOD1 mutation.

1. Introduction

In 5–10% of patients with amyotrophic lateral sclerosis (ALS), a positive family history for ALS can be detected (familial ALS, fALS) (Chiò et al., 2011), and the research field of ALS continues to develop rapidly with multiple disease gene discoveries (Brenner and Weishaupt, 2019). An autosomal dominant inheritance of a GGGGCC hexanucleotide repeat in the first intron of the C9orf72 gene is the most common cause of fALS in people of Northern European ancestry and is also a common cause of familial frontotemporal dementia (FTD) (Byrne et al., 2012, Renton et al., 2014, DeJesus-Hernandez et al., 2011, Rohrer et al., 2015). In the original publication describing that phosphorylated 43 kDa TAR DNA-binding protein (pTDP-43) pathology in ALS disseminates in a sequential pattern that permits recognition of four neuropathological stages (Brettschneider et al., 2013), the eleven cases with C9orf72 repeat expansion displayed the same sequential spreading pattern as the nonexpansion cases despite a greater regional burden of lesions. The search for in vivo biomarkers of disease onset and progression in C9orf72 repeat expansion carriers has yielded promising candidates, as summarized in a recent review (Floeter et al., 2018), with particular interest in neuroimaging as a biomarker because it offers – beyond the correlation of neuropathological data and ex vivo MRI (Pallebage-Gamarallage et al., 2018) – the option of visualizing pathological changes in the brains of living patients.

For the demonstration of cerebral TDP43 pathology according to the principles of the neuropathological staging concept of ALS (Brettschneider et al., 2013, Braak et al., 2013, Braak et al., 2017), a neuroimaging approach exists that uses a tract of interest (TOI)-based diffusion tensor imaging (DTI) analysis technique to demonstrate ALS-specific corticoefferent tract pathology in vivo (Kassubek et al., 2014, Kassubek et al., 2018). In the current study, a DTI- and TOI-based analysis was performed in patients with fALS and C9orf72 expansion, comparing their findings with healthy controls and genetic ALS patients with SOD1 mutation, to investigate the in vivo correlates of the neuropathological propagation pattern.

2. Materials and methods

2.1. Subjects and patient characteristics

Forty-two patients with confirmed ALS mutations were included who clinically met the diagnostic criteria according to the El Escorial diagnostic criteria (Ludolph et al., 2015). The fALS patients included 27 C9orf72 expansion carriers and a control group with a different mutation, i.e., 15 SOD1 mutation carriers. Four of the C9orf72 expansion carriers fulfilled the criteria for ALS-FTD of the behavioral type (bvFTD) according to Rascovsky criteria (Rascovsky et al., 2011). Details of demographics, clinical data including ALS-FRS-R (Cedarbaum et al., 1999), and disease duration for all groups are summarized in Table 1.

Table 1.

(A) Patients' and controls' gender, age, and scanner distribution. (B) Subjects' characteristics including cognitive profile measured with the Edinburgh cognitive and behavioural ALS screen (ECAS) for statistical comparison.

(A)
	gender (m/f)	Age/years	age range/years	MRI scanner 1.5 T/3.0 T
C9orf72	17/10	62 ± 12	34–78	22/5
controls A	23/9	59 ± 16	24–82	26/6
p (t-test)	0.47	0.49	–	0.98
SOD1	8/7	55 ± 13	37–79	12/3
controls B	12/9	54 ± 14	24–73	17/4
p (t-test)	0.69	0.90	–	0.94

(B)
	ECAS total score	memory	visuospatial	language	Verbal fluency	executive function	ALS-FRS-R median (range)	dis.dur./months median (range)	years of education	Handedness (right/left)	site of onset (spinal/bulbar)
C9orf72	30 ± 8	13 ± 5	11 ± 2	22 ± 6	15 ± 5	30 ± 8	40 (34 – 48)	12 (3 – 37)	12.8 ± 3.8	26/1.	18/9
SOD1	107 ± 8	16 ± 2	12 ± 1	24 ± 4	17 ± 4.3	38 ± 4	44 (29 – 48)	13 (4 – 48)	13.7 ± 3.3	13/2.	15/0

FALS patients were compared with a group of 32 age- and gender-matched controls. Gross brain pathology, including vascular brain alterations, could be excluded by conventional MRI including fluid attenuated inversion recovery sequences. All control individuals lacked a family history of neuromuscular disease and had no history of neurologic, psychiatric, or other major medical illnesses and were recruited from among spouses of patients and by word of mouth.

All participants provided written informed consent for the study protocol according to institutional guidelines which had been approved by the Ethics Committee of Ulm University, Germany (No. 19/12).

2.2. Cognitive analysis

In patients, cognition was measured with the German version (Lulé et al., 2015) of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) (Abrahams et al., 2014) by a trained psychologist. The ECAS addresses cognitive domains of language, verbal fluency, executive functions (ALS specific functions), and memory and visuospatial functions (ALS non-specific functions). Using the ECAS behavioral score, patients’ behavioral alterations were reported by primary caregivers. Statistics for neuropsychology were performed using Statistical package for Social Sciences (SPSS version 21.0 IBM). Cognitive performance between groups was calculated with ANOVA and post-hoc Scheffé. Threshold of p < 0.05 was adopted for statistical significance.

2.3. Genetic analysis

DNA was extracted from whole EDTA-containing venous blood samples as previously described: analysis of the C9orf72 repeat length was performed by fragment length analysis and repeat-primed PCR (RP-PCR) using previously published primers (Zondler et al., 2016). Since PCR-based methods cannot determine the size of larger expanded repeat-alleles, samples with a sawtooth pattern in the RP-PCR were further analyzed using Southern blot (DeJesus-Hernandez et al., 2011). SOD1 genotyping was performed based on Sanger Sequencing using previously published primers (Waibel et al., 2010).

All SOD1 mutations were missense mutations. The SOD1-patients had nine different mutations. The p.R116G mutation, the most frequent SOD1 mutation in Germany, was represented four times, the p.H44R three times, and the p.V149A two times. Therefore we had a rather wide variety of SOD1 mutations in our SOD1 cohort. The number of repeats in the C9orf72-patients ranged from 750 to 3000. Given the heterogeneity in disease duration and rate of progression among different SOD1 mutations and the wide range of expansion lengths in our C9orf72-patients, we judge the results to be reliable independent of the type of SOD1 mutations and the number of repeats in C9orf72.

The SOD1- as well as the C9orf72-associated ALS patients were from all over Germany. Two C9orf72-patients were from outside Germany, Austria and France, and one SOD1-patient was from Sweden. About 34% of the C9orf72-patients had a FTD co-morbidity, and one patient with a p.H49R mutation in SOD1 presented symptoms that were consistent with a beginning bvFTD. The majority of the other family members with a C9orf72 expansion had ALS alone, a subset of the index patients displayed cognitive or behavioural symptoms of FTD. ALS/FTD co-morbidity was rarely observed in those family members.

2.4. MRI acquisition

MRI scans were obtained with two scanners, a 1.5 Tesla Magnetom Symphony and a 3.0 T head scanner Allegra (both, Siemens Medical, Erlangen, Germany). The 1.5 T DTI study protocol consisted of 52 volumes (64 slices, 128x128 pixels, slice thickness 2.8 mm, pixel size 2.0 mm × 2.0 mm), representing 48 gradient directions (b = 1000 s/mm²) and four scans with b = 0; TE and TR were 95 ms and 8000 ms. The 3.0 T DTI study protocol consisted of 49 volumes (52 slices, 96x128 pixels, slice thickness 2.2 mm, pixel size 2.2 mm × 2.2 mm), representing 48 gradient directions (b = 1000 s/mm²) and one scan with b = 0; TE and TR were 85 ms and 7600 ms.

2.5. Data analysis

The analysis of the DTI data was performed by use of the software Tensor Imaging and Fiber Tracking (TIFT – Müller et al., 2007A). The algorithms used in this study have been previously described in detail (Kassubek et al., 2014, Kassubek et al., 2018, Müller and Kassubek, 2018). Stereotaxic normalization to the Montreal Neurological Institute (MNI) space was performed iteratively using study-specific templates (Müller et al., 2009). From the stereotaxically normalized DTI data sets of all subjects, fractional anisotropy (FA) maps were quantitatively calculated to map white matter microstructure (Le Bihan et al., 2001). A Gaussian filter of 8 mm full width at half maximum was applied for smoothing of FA maps for a good balance between sensitivity and specificity (Unrath et al., 2010). Finally, FA maps were corrected for the covariate age. Data were harmonized between the two scanners used (Müller et al., 2016) – the harmonization procedure has already been established at multicenter level cross-sectionally (Müller et al., 2013, Müller et al., 2016) and longitudinally (Kalra et al., 2020). In addition, the ratio of scans acquired at each scanner was almost the same between the subject groups, i.e., the age-matched controls’ data sets were matched to the ALS groups for number of scans at the different scanners (for details see Table 1).

Statistical comparison by Student’s t-test was performed voxel-wise for FA values to detect changes between the subject groups (whole brain-based spatial statistics, WBSS). Voxels with FA values below 0.2 were not considered for statistical comparison, since cortical grey matter shows FA values up to 0.2 (Kunimatsu et al., 2004). Statistical results were corrected for multiple comparisons using the false-discovery-rate (FDR) algorithm at p < 0.05 (Genovese et al., 2002). Further reduction of the alpha error was performed by a spatial correlation algorithm that eliminated isolated voxels or small isolated groups of voxels in the size range of the smoothing kernel leading to a threshold cluster size of 256 voxels (Kassubek et al., 2018).

Defined tract systems according to the ALS-staging system (Braak et al., 2013, Ludolph and Brettschneider, 2015) were identified with the tract-of interest (TOI) approach (Kassubek et al., 2014, Kassubek et al., 2018). TOIs for the four ALS stages were the corticospinal tract (CST, representative for stage 1), the corticorubral and corticopontine tracts (corresponding to stage 2), the corticostriatal pathway (stage 3), and the proximal perforant path (stage 4). As a reference path, a tract originating from the corpus callosum (CC) area V was used where no involvement in ALS-associated neurodegeneration could be anticipated. Tract-wise fractional anisotropy statistics (TFAS (Müller et al., 2007B, Müller et al., 2013)) was performed by statistically comparing the FA values in each tract system between two subject groups (Student’s t-test), not considering FA-values < 0.2. The use of Student’s t-test was justified since the groups were large enough to show a Gaussian distribution of FA values.

3. Results

3.1. Whole brain-based spatial statistics of FA maps

The WBSS comparison at the group level for the 27 C9orf72 fALS patients vs 32 controls demonstrated widespread regional alterations (cluster size 63709 mm³) at FDR-corrected p < 0.05 (Fig. 1): FA reductions were observed mainly along the CST (corresponding to neuropathological stage 1 of ALS – Kassubek et al., 2018) with projections to frontal areas (corresponding to neuropathological stages 2 and 3) and to the hippocampal areas (corresponding to neuropathological stage 4).

Fig. 1.

Whole brain-based spatial statistics (WBSS) of FA maps of fALS patients vs controls. WBSS of FA maps (p < 0.05, False-discovery-rate (FDR) corrected) demonstrated one cluster of regional FA reductions for C9orf72 fALS patients vs controls. The SOD1 mutation did not show any significant cluster of FA reduction when compared to age- and gender-matched controls.

The comparison at the group level by WBSS for the 15 fALS patients with SOD1 mutation vs 21 matched controls demonstrated no significant clusters of regional alterations at FDR-corrected p < 0.05.

3.2. Differences of FA in the specific tract systems

The analysis of the FA differences in the ALS-related tract systems by use of TFAS showed significant differences of the averaged FA values between the C9orf27 fALS patients and control groups. Changes were most prominent in the CST, followed by FA reductions in the corticorubral and corticopontine tracts (i.e., tracts related to ALS stages 1 and 2) (Fig. 2). Further FA reductions could be observed for the corticostriatal pathway and for the proximal perforant path (i.e., the tracts related to ALS stages 3 and 4). For the grand average of the stage-related tract systems, significant FA reductions were observed accordingly. TFAS showed no significant differences of the averaged FA values between the SOD1 fALS patients and controls (Fig. 2). No significant FA alterations were observed in the reference path for any group comparison.

Fig. 2.

Tractwise fractional anisotropy statistics (TFAS) of FA maps at the group level for fALS patients compared to controls. TFAS demonstrated significant regional FA reductions in ALS-related tract systems and in the grand average between C9orf72 fALS patients and controls. SOD1 mutation fALS patients did not show significant alterations when compared to age- and gender-matched controls. Error bars, SEM. * p < 0.05, ** p < 0.001.

3.3. ALS staging at the individual level

ALS staging categorization was performed for all ALS patients, and 89% of the C9orf72 fALS patients could be staged (Supplementary Fig. 1). After division into bulbar onset and spinal onset, the stage distribution of the spinal and bulbar onset was similar to the distribution of the whole group so that no significant difference in terms of staging could be observed between spinal and bulbar onset. The percentage of stageable C9orf72 fALS was higher than in previous studies in sporadic ALS patients (Kassubek et al., 2018). In contrast, SOD1-associated fALS patients showed FA reductions along the CST compared to controls, but no significant changes of the other tract systems according to the staging scheme so that no staging categorization was possible in any of these fALS subjects. After division into bulbar onset and spinal onset, the stage distribution of the spinal and bulbar onset was similar to the distribution of the whole group so that no significant difference in terms of staging could be observed between spinal and bulbar onset.

3.4. Neuropsychology

C9orf72 patients performed worse in executive function (ANOVA F = 4.09, p = 0.03 with post-hoc Scheffé p = 0.041) and total score (trend ANOVA F = 3.06, p = 0.06 with post-hoc Scheffé p = 0.069) compared to SOD1 patients. No differences between groups was observed for any of the other cognitive domains.

4. Discussion

This DTI study with a TOI-based analysis showed the same corticoefferent tract involvement pattern according to the neuropathological staging scheme in fALS patients with C9orf72 expansion as previously reported for a large group of sporadic ALS patients (Kassubek et al., 2018), whereas this pattern could not be observed in ALS patients with SOD1 mutation. On the basis of these neuroimaging data, the proposed staging scheme for ALS (Braak et al., 2013) could be confirmed in vivo for fALS with C9orf72 expansion, in analogy with the demonstration of corticofugal tract involvement in ‘classical’ ALS (Kassubek et al., 2014, Kassubek et al., 2018) and in restricted ALS phenotypes (Rosenbohm et al., 2016, Müller et al., 2018a, Müller et al., 2018b, Müller et al., 2018c, Müller et al., 2019). Given that the neuropsychological results demonstrated that C9orf72 patients performed significantly worse compared to SOD1 patients, cognitive data underline the understanding that C9orf72 ALS-patients resemble the subgroup within ALS that is closer to FTD according to neuropsychology than other genetic mutation carriers.

This is the first DTI study in patients with fALS with a hypothesis-guided TOI-based approach that addressed the white matter tracts corresponding to the pTDP-43-based neuropathology pattern. Previous data-driven DTI studies in fALS patients with C9orf72 expansion in cross-sectional and longitudinal design demonstrated alterations in motor tracts, including the CST and the motor segment of the corpus callosum (Floeter et al., 2018, Agosta et al., 2017) and in the frontal white matter (Westeneng et al., 2016). In addition, further white matter areas and several white matter tracts were found to be affected: extensive cortico-striatal degeneration has been previously described in C9orf72-associated ALS, consistent with stage 3 (Omer et al., 2017). Furthermore, extensive temporal lobe white matter alterations were also identified in C9orf72 repeat carriers (Bede et al., 2018). The current hypothesis-based approach was able to define an involvement pattern that per se did not differ from sporadic ALS patients but was identical to that proposed by the neuropathological data (Brettschneider et al., 2013). In contrast to the C9orf72 expansion-associated fALS, the SOD1-associated fALS patients showed no TOI-based abnormalities, probably due to a different pattern of neuropathology. The lack of significant cerebral alterations in the SOD1 patients is in accordance with a previous study in 20 patients with SOD1-associated ALS who demonstrated a relative preservation of brain motor structural networks as assessed by DTI (Agosta et al., 2018).

This study was not without limitations. First, the neuropathological confirmation of the neuroimaging transfer of the ALS propagation scheme in the brain by autopsy results was not available for the patients studied. A second drawback was the limited number of available genotyped fALS patients, although it seems safe to conclude that the data from the original neuropathological study (Brettschneider et al., 2013) were sufficient to be generalized for all C9orf72 expansion-associated fALS cases. In addition, DTI data from two different scanners had to be included. However, given that controls and patients were equally distributed over scanner types, the group comparisons can be regarded as matched for scanner type. Finally, future studies should include longitudinal data to investigate the possibility of tracking disease propagation, as previously demonstrated for sporadic ALS patients (Kassubek et al., 2018). Longitudinal tracking could optimally be performed in presymptomatic mutation carriers with respect to stagewise propagation, given that previous studies captured CST, CC and thalamic pathology long before projected symptom onset (Wen et al., 2019, Feis et al., 2019, Chen and Kantarci, 2020).

In summary, the tract-specific DTI analysis demonstrated alterations of ALS-related tract systems for C9orf72-associated fALS and, thus, might be a promising candidate biomarker for patients with C9orf72 repeat expansion (Floeter and Gendron, 2018). Potentially, this approach will enable to detect effects of disease-modifying therapeutic interventions in the future, provided that the longitudinal TOI mapping reveals identical patterns as in sporadic ALS patients (Kassubek et al., 2018, Kassubek and Müller, 2020). Perhaps even more importantly, persons known to carry the C9orf72 expansion could receive MRI and TOI-based analyses at presymptomatic clinical stages in order to determine the time point in the disease course when the in vivo detection of the neuropathological disease stages is possible.

5. Statement

All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

CRediT authorship contribution statement

Hans-Peter Müller: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software,Visualization, Writing - original draft. Kelly Del Tredici: Validation, Writing - review & editing. Dorothée Lulé: Formal analysis (Neuropsychology), Writing - review & editing. Kathrin Müller: Formal analysis (Genetic data), Writing - review & editing. Jochen H. Weishaupt: Validation, Writing - review & editing. Albert C. Ludolph: Validation, Writing - review & editing. Jan Kassubek: Conceptualization, Investigation, Visualization, Data curation, Supervision, Writing - original draft.

Funding

This study was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG Grant Number LU 336/15-1), the German Network for Motor Neuron Diseases (BMBF 01GM1103A), and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

The following are the Supplementary data to this article: